A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF
LUSPATERCEPT (ACE-536) VS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO
REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) VERY LOW, LOW, OR
INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS) IN ERYTHROPOIESISSTIMULATING AGENT (ESA)-NAIVE PARTICIPANTS WHO ARE NON-TRANSFUSION DEPENDENT
(NTD): THE ¿ELEMENT-MDS¿ TRIAL
- Registry ID
- CA056025
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA CO.
- Start date
- 2024-04-18
- Last update
- 2023-06-30
Conditions
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST
COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON
APPROVED C5-INHIBITOR THERAPY
- A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH
ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
- FEASIBILITY AND EFFICACY OF INTRAVENOUS FERRIC DERISOMALTOSE TO CORRECT PRE-OPERATIVE IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING GYNECOLOGIC ONCOLOGY SURGERY: A PILOT RANDOMIZED DOUBLE BLINDED PARALLEL GROUP PLACEBO-CONTROLLED STUDY
- A PHASE 3B, OPEN-LABEL, SINGLE-ARM, ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO HAVE PARTICIPATED IN OTHER LUSPATERCEPT(ACE-536) CLINICAL TRIALS
- A RANDOMIZED DOUBLE-BLINDED PHASE II STUDY TO DETERMINE TREATMENT PROTOCOL FOR HEMOGLOBIN OPTIMIZATION TO PREVENT TRANSFUSION AND ADVERSE EVENTS IN PERIOPERATIVE PATIENTS WITH IRON RESTRICTED ANEMIA ¿ HOPE-HB STUDY
- PROTOCOL TITLE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FERRIC CARBOXYMALTOSE (US TRADE NAME: INJECTAFER) AS TREATMENT FOR HEART FAILURE WITH IRON DEFICIENCY
View on source registry